Related references
Note: Only part of the references are listed.Mechanisms of toxicity associated with six tyrosine kinase inhibitors in human hepatocyte cell lines
Cecile Mingard et al.
JOURNAL OF APPLIED TOXICOLOGY (2018)
Cytochromes P450 1A2 and 3A4 Catalyze the Metabolic Activation of Sunitinib
Gracia M. Amaya et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2018)
LC-MS/MS reveals the formation of reactive ortho-quinone and iminium intermediates in saracatinib metabolism: Phase I metabolic profiling
Mohamed W. Attwa et al.
CLINICA CHIMICA ACTA (2018)
Identification of Ketene-Reactive Intermediate of Erlotinib Possibly Responsible for Inactivation of P450 Enzymes
Huimin Zhao et al.
DRUG METABOLISM AND DISPOSITION (2018)
Effects of 31 FDA approved small-molecule kinase inhibitors on isolated rat liver mitochondria
Jun Zhang et al.
ARCHIVES OF TOXICOLOGY (2017)
Novel Pathways of Ponatinib Disposition Catalyzed By CYP1A1 Involving Generation of Potentially Toxic Metabolites
De Lin et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2017)
Identification and characterization of in vitro phase I and reactive metabolites of masitinib using a LC-MS/MS method: bioactivation pathway elucidation
Sawsan M. Amer et al.
RSC ADVANCES (2017)
Hepatocellular Toxicity Associated with Tyrosine Kinase Inhibitors: Mitochondrial Damage and Inhibition of Glycolysis
Franziska Paech et al.
FRONTIERS IN PHARMACOLOGY (2017)
Drug-Induced Liver Injury: Advances in Mechanistic Understanding That Will Inform Risk Management
M. Mosedale et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
HLA-B*57:01 Confers Susceptibility to Pazopanib-Associated Liver Injury in Patients with Cancer
Chun-Fang Xu et al.
CLINICAL CANCER RESEARCH (2016)
Metabolic activation and drug-induced liver injury: in vitro approaches for the safety risk assessment of new drugs
M. Jose Gomez-Lechon et al.
JOURNAL OF APPLIED TOXICOLOGY (2016)
Effect of the CYP3A5 and ABCB1 genotype on exposure, clinical response and manifestation of toxicities from sunitinib in Asian patients
Y. L. Teo et al.
PHARMACOGENOMICS JOURNAL (2016)
Comprehensive genome-wide evaluation of lapatinib-induced liver injury yields a single genetic signal centered on known risk allele HLA-DRB1*07:01
L. R. Parham et al.
PHARMACOGENOMICS JOURNAL (2016)
P450 3A-Catalyzed O-Dealkylation of Lapatinib Induces Mitochondrial Stress and Activates Nrf2
Marsha Rebecca Eno et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2016)
Cytochrome P450 Mediated Bioactivation of Saracatinib
Jiaming Chen et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2016)
Small-molecule kinase inhibitors: an analysis of FDA-approved drugs
Peng Wu et al.
DRUG DISCOVERY TODAY (2016)
Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial
Jeffrey H. Lipton et al.
LANCET ONCOLOGY (2016)
Cytochrome P450 3A4 and CYP3A5-Catalyzed Bioactivation of Lapatinib
Joanna K. Towles et al.
DRUG METABOLISM AND DISPOSITION (2016)
Predicting Toxicities of Reactive Metabolite-Positive Drug Candidates
Amit S. Kalgutkar et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 55 (2015)
Metabolism-related pharmacokinetic drug-drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations
Yi Ling Teo et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Hepatotoxicity with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A meta-analysis of randomized clinical trials
Pooja Ghatalia et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2015)
Mechanism-based inactivation of CYP450 enzymes: a case study of lapatinib
Han Kiat Ho et al.
DRUG METABOLISM REVIEWS (2015)
Sunitinib-ibuprofen drug interaction affects the pharmacokinetics and tissue distribution of sunitinib to brain, liver, and kidney in male and female mice differently
Christine Li Ling Lau et al.
FUNDAMENTAL & CLINICAL PHARMACOLOGY (2015)
The chemical, genetic and immunological basis of idiosyncratic drug-induced liver injury
A. Tailor et al.
HUMAN & EXPERIMENTAL TOXICOLOGY (2015)
Drug-induced liver injury: Interactions between drug properties and host factors
Minjun Chen et al.
JOURNAL OF HEPATOLOGY (2015)
Impact of single nucleotide polymorphisms on severe hepatotoxicity induced by EGFR tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring EGFR mutations
Eri Sugiyama et al.
LUNG CANCER (2015)
Regorafenib impairs mitochondrial functions, activates AMP-activated protein kinase, induces autophagy, and causes rat hepatocyte necrosis
Zuquan Weng et al.
TOXICOLOGY (2015)
Hepatotoxicity of molecular targeted therapy
Bozenna Karczmarek-Borowska et al.
WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY (2015)
Formation of reactive metabolites and management of tyrosine kinase inhibitor-induced hepatotoxicity: a literature review
Yi Ling Teo et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2015)
Toxicity of targeted therapy: Implications for response and impact of genetic polymorphisms
Sariah Liu et al.
CANCER TREATMENT REVIEWS (2014)
Prospective Validation of HLA-DRB1*07:01 Allele Carriage As a Predictive Risk Factor for Lapatinib-Induced Liver Injury
Daniel J. Schaid et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Structural identification of imatinib cyanide adducts by mass spectrometry and elucidation of bioactivation pathway
Austin C. Li et al.
RAPID COMMUNICATIONS IN MASS SPECTROMETRY (2014)
In Vitro Assessment of Time-Dependent Inhibitory Effects on CYP2C8 and CYP3A Activity by Fourteen Protein Kinase Inhibitors
Anne M. Filppula et al.
DRUG METABOLISM AND DISPOSITION (2014)
Pathway-Dependent Inhibition of Paclitaxel Hydroxylation by Kinase Inhibitors and Assessment of Drug-Drug Interaction Potentials
Yedong Wang et al.
DRUG METABOLISM AND DISPOSITION (2014)
Studies on the Role of Metabolic Activation in Tyrosine Kinase Inhibitor-Dependent Hepatotoxicity: Induction of CYP3A4 Enhances the Cytotoxicity of Lapatinib in HepaRG Cells
Klarissa D. Hardy et al.
DRUG METABOLISM AND DISPOSITION (2014)
Regorafenib: A Novel Multitargeted Tyrosine Kinase Inhibitor for Colorectal Cancer and Gastrointestinal Stromal Tumors
Daniel J. Crona et al.
ANNALS OF PHARMACOTHERAPY (2013)
Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients
Cen Xie et al.
BRITISH JOURNAL OF PHARMACOLOGY (2013)
Risk of tyrosine kinase inhibitors-induced hepatotoxicity in cancer patients: A meta-analysis
Yi Ling Teo et al.
CANCER TREATMENT REVIEWS (2013)
Hepatotoxicity of Tyrosine Kinase Inhibitors: Clinical and Regulatory Perspectives
Rashmi R. Shah et al.
DRUG SAFETY (2013)
The Generation, Detection, and Effects of Reactive Drug Metabolites
Andrew V. Stachulski et al.
MEDICINAL RESEARCH REVIEWS (2013)
Genetic characterization to improve interpretation and clinical management of hepatotoxicity caused by tyrosine kinase inhibitors
Colin F. Spraggs et al.
PHARMACOGENOMICS (2013)
Effect of CYP3A4 inducer dexamethasone on hepatotoxicity of lapatinib: clinical and in vitro evidence
Yi Ling Teo et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Lapatinib-Induced Liver Injury Characterized by Class II HLA and Gilbert's Syndrome Genotypes
C. F. Spraggs et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
The HepaRG cell line: a unique in vitro tool for understanding drug metabolism and toxicology in human
Tommy B. Andersson et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2012)
Drug-Drug Interaction Potential of Marketed Oncology Drugs: In Vitro Assessment of Time-Dependent Cytochrome P450 Inhibition, Reactive Metabolite Formation and Drug-Drug Interaction Prediction
Jane R. Kenny et al.
PHARMACEUTICAL RESEARCH (2012)
Oxidative stress is involved in Dasatinib-induced apoptosis in rat primary hepatocytes
Tao Xue et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2012)
Interaction of Lapatinib with Cytochrome P450 3A5
Eric Chun Yong Chan et al.
DRUG METABOLISM AND DISPOSITION (2012)
Human Metabolism of Lapatinib, a Dual Kinase Inhibitor: Implications for Hepatotoxicity
Stephen Castellino et al.
DRUG METABOLISM AND DISPOSITION (2012)
Bioactivation of Drugs: Risk and Drug Design
John S. Walsh et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 51, 2011 (2011)
Structural Alert/Reactive Metabolite Concept as Applied in Medicinal Chemistry to Mitigate the Risk of Idiosyncratic Drug Toxicity: A Perspective Based on the Critical Examination of Trends in the Top 200 Drugs Marketed in the United States
Antonia F. Stepan et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2011)
Metabolic Intermediate Complex Formation of Human Cytochrome P450 3A4 by Lapatinib
Hideo Takakusa et al.
DRUG METABOLISM AND DISPOSITION (2011)
HepaRG Cells: A Human Model to Study Mechanisms of Acetaminophen Hepatotoxicity
Mitchell R. McGill et al.
HEPATOLOGY (2011)
HLA-DQA1*02:01 Is a Major Risk Factor for Lapatinib-Induced Hepatotoxicity in Women With Advanced Breast Cancer
Colin F. Spraggs et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Stable Expression, Activity, and Inducibility of Cytochromes P450 in Differentiated HepaRG Cells
Sebastien Antherieu et al.
DRUG METABOLISM AND DISPOSITION (2010)
Cytochrome P450-Mediated Bioactivation of the Epidermal Growth Factor Receptor Inhibitor Erlotinib to a Reactive Electrophile
Xiaohai Li et al.
DRUG METABOLISM AND DISPOSITION (2010)
Metabolism considerations for kinase inhibitors in cancer treatment
Derek R. Duckett et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2010)
Mechanism-Based Inactivation of Cytochrome P450 3A4 by Lapatinib
Woon Chien Teng et al.
MOLECULAR PHARMACOLOGY (2010)
Clinical pharmacokinetics of tyrosine kinase inhibitors
Nielka P. van Erp et al.
CANCER TREATMENT REVIEWS (2009)
Bioactivation of the Epidermal Growth Factor Receptor Inhibitor Gefitinib: Implications for Pulmonary and Hepatic Toxicities
Xiaohai Li et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2009)
Can In Vitro Metabolism-Dependent Covalent Binding Data Distinguish Hepatotoxic from Nonhepatotoxic Drugs? An Analysis Using Human Hepatocytes and Liver S-9 Fraction
Jonathon N. Bauman et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2009)
Current Concepts of Mechanisms in Drug-Induced Hepatotoxicity
Stefan Russmann et al.
CURRENT MEDICINAL CHEMISTRY (2009)
Characterization of Dasatinib and Its Structural Analogs as CYP3A4 Mechanism-Based Inactivators and the Proposed Bioactivation Pathways
Xiaohai Li et al.
DRUG METABOLISM AND DISPOSITION (2009)
Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530
Tim P. Green et al.
MOLECULAR ONCOLOGY (2009)
Masitinib (AB1010), a Potent and Selective Tyrosine Kinase Inhibitor Targeting KIT
Patrice Dubreuil et al.
PLOS ONE (2009)
Role of Hepatic Transporters in the Disposition and Hepatotoxicity of a HER2 Tyrosine Kinase Inhibitor CP-724,714
Bo Feng et al.
TOXICOLOGICAL SCIENCES (2009)
Can in vitro metabolism-dependent covalent binding data in liver microsomes distinguish hepatotoxic from nonhepatotoxic drugs? An analysis of 18 drugs with consideration of intrinsic clearance and daily dose
R. Scott Obach et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2008)
Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3
Dana D. Hu-Lowe et al.
CLINICAL CANCER RESEARCH (2008)
Lapatinib: A dual inhibitor of human epidermal growth factor receptor tyrosine kinases
Patrick J. Medina et al.
CLINICAL THERAPEUTICS (2008)
Circumventing the crabtree effect: Replacing media glucose with galactose increases susceptibility of HepG2 cells to mitochondrial toxicants
Lisa D. Marroquin et al.
TOXICOLOGICAL SCIENCES (2007)
The human hepatoma HepaRG cells: A highly differentiated model for studies of liver metabolism and toxicity of xenobiotics
Andre Guillouzo et al.
CHEMICO-BIOLOGICAL INTERACTIONS (2007)
Approval summary: Sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma
Vicki L. Goodman et al.
CLINICAL CANCER RESEARCH (2007)
Sunitinib: From rational design to clinical efficacy
Laura Q. M. Chow et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Hepatobiliary transporters and drug-induced cholestasis
Christiane Pauli-Magnus et al.
HEPATOLOGY (2006)
Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells
C Aninat et al.
DRUG METABOLISM AND DISPOSITION (2006)
Tyrosine kinases as targets for cancer therapy
DS Krause et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Drug-protein adducts: An industry perspective on minimizing the potential for drug bioactivation in drug discovery and development
DC Evans et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2004)
A review of the common properties of drugs with idiosyncratic hepatotoxicity and the multiple determinant hypothesis for the manifestation of idiosyncratic drug toxicity
AP Li
CHEMICO-BIOLOGICAL INTERACTIONS (2002)
Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants
AT Dinkova-Kostova et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Share Paper
